Company is at the forefront of medical technology, specializing in photobiomodulation, a cutting-edge treatment with extensive clinical backing. Their flagship product is a class-two medical device endorsed by over 6,000 humans and 600 double-blind studies. Renowned for its efficacy, it is utilized by elite athletes and the military. It is currently being evaluated by the NFL for its potential in preventing and treating traumatic brain injuries.  Since 2017, the company has been a pivotal player in the opioid crisis, providing a non-pharmacological alternative that has helped numerous individuals overcome pain and dependency on harmful drugs. Since then, they have expanded their light therapy treatment, which is being approved by many medical providers and accepted by many major insurance companies. The company is expanding across the US with their light therapy clinics. They currently have seven open, with three more opening this quarter. They are currently expanding via a franchise solution.

The owners are seeking an investment of $10,000,000, for a 7-year note at 2% above prime interest rate.  Amounts, including interest, not paid in full by maturity date convert to equity at post-money 20% discount.  Equity in the company of up to 10% available.

A full Investor Deck is available to interested, qualified parties upon receipt of an executed NDA and financial profile.